RxDoctor Payments Data

Alisha Pratt, DO

Family Medicine · Turlock, CANPI 1730319906

Payments from drug & device makers

$1,916in general payments, 2019–2025

Across 113 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$316
  • Pfizer$289
  • AstraZeneca$254
  • Boehringer Ingelheim$198
  • Johnson & Johnson$146
  • Lilly USA, LLC$106
  • plus $607 from 20 others

What the payments were for

  • Consulting fees$1759%
  • Food & beverage$1,73090%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,916 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$195,773
Medicare patients
535
Services billed
2,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate101$120,216
JardianceEmpagliflozin75$75,626
EliquisApixaban76$72,571
XareltoRivaroxaban46$58,667
OzempicSemaglutide48$56,051
TrulicityDulaglutide35$37,731
TradjentaLinagliptin31$20,379
RexultiBrexpiprazole13$17,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,099
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$14,182
MyrbetriqMirabegron14$14,005
InvokanaCanagliflozin12$13,279
Atorvastatin Calcium793$12,297
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$10,868
Spiriva RespimatTiotropium Bromide16$10,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$47$120,216101 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$198$106,827122 claims
PfizerEliquis, Paxlovid$289$75,43099 claims
Johnson & JohnsonXarelto, Invokana$146$71,94658 claims
Novo NordiskOzempic$60$56,05148 claims
Lilly USA, LLCTrulicity$106$37,73135 claims
GSKTrelegy Ellipta, Anoro Ellipta$20$27,96739 claims
Otsuka America Pharmaceutical, Inc.Rexulti$33$17,41513 claims
AstraZenecaBreztri Aerosphere$254$6,74511 claims
AbbVieSynthroid$68$3,20329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →